Aggrecan Antibody - #DF7561

(27)   (20)  
Product: Aggrecan Antibody
Catalog: DF7561
Description: Rabbit polyclonal antibody to Aggrecan
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Rabbit, Dog
Mol.Wt.: 70,150,250 kDa; 261kD(Calculated).
Uniprot: P16112
RRID: AB_2841055

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Sheep(100%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
Aggrecan Antibody detects endogenous levels of total Aggrecan.
RRID:
AB_2841055
Cite Format: Affinity Biosciences Cat# DF7561, RRID:AB_2841055.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ACAN; AGC 1; AGC1; AGCAN; Aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody A0122); Aggrecan 1; Aggrecan core protein; Aggrecan proteoglycan; Aggrecan structural proteoglycan of cartilage; Aggrecan1; ATEGQV; Cartilage specific proteoglycan core protein; Chondroitin sulfate proteoglycan 1; Chondroitin sulfate proteoglycan 1 large aggregating proteoglycan antigen identified by monoclonal antibody A0122; Chondroitin sulfate proteoglycan core protein 1; CSPG 1; CSPG1; CSPGCP; JSCATE; Large aggregating proteoglycan; mcspg; mgsk16; MSK 16; MSK16; SEDK;

Immunogens

Immunogen:
Uniprot:

P16112(PGCA_HUMAN) >>Visit HPA database.

Gene(ID):
ACAN(176)
Expression:
P16112 PGCA_HUMAN:

Restricted to cartilages.

Sequence:
MTTLLWVFVTLRVITAAVTVETSDHDNSLSVSIPQPSPLRVLLGTSLTIPCYFIDPMHPVTTAPSTAPLAPRIKWSRVSKEKEVVLLVATEGRVRVNSAYQDKVSLPNYPAIPSDATLEVQSLRSNDSGVYRCEVMHGIEDSEATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVRYPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARLATTGQLYLAWQAGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYVHANQTGYPDPSSRYDAICYTGEDFVDIPENFFGVGGEEDITVQTVTWPDMELPLPRNITEGEARGSVILTVKPIFEVSPSPLEPEEPFTFAPEIGATAFAEVENETGEATRPWGFPTPGLGPATAFTSEDLVVQVTAVPGQPHLPGGVVFHYRPGPTRYSLTFEEAQQACLRTGAVIASPEQLQAAYEAGYEQCDAGWLRDQTVRYPIVSPRTPCVGDKDSSPGVRTYGVRPSTETYDVYCFVDRLEGEVFFATRLEQFTFQEALEFCESHNATLATTGQLYAAWSRGLDKCYAGWLADGSLRYPIVTPRPACGGDKPGVRTVYLYPNQTGLPDPLSRHHAFCFRGISAVPSPGEEEGGTPTSPSGVEEWIVTQVVPGVAAVPVEEETTAVPSGETTAILEFTTEPENQTEWEPAYTPVGTSPLPGILPTWPPTGAATEESTEGPSATEVPSASEEPSPSEVPFPSEEPSPSEEPFPSVRPFPSVELFPSEEPFPSKEPSPSEEPSASEEPYTPSPPVPSWTELPSSGEESGAPDVSGDFTGSGDVSGHLDFSGQLSGDRASGLPSGDLDSSGLTSTVGSGLPVESGLPSGDEERIEWPSTPTVGELPSGAEILEGSASGVGDLSGLPSGEVLETSASGVGDLSGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETTAPGVEEISGLPSGEVLETTAPGVDEISGLPSGEVLETTAPGVEEISGLPSGEVLETSTSAVGDLSGLPSGGEVLEISVSGVEDISGLPSGEVVETSASGIEDVSELPSGEGLETSASGVEDLSRLPSGEEVLEISASGFGDLSGLPSGGEGLETSASEVGTDLSGLPSGREGLETSASGAEDLSGLPSGKEDLVGSASGDLDLGKLPSGTLGSGQAPETSGLPSGFSGEYSGVDLGSGPPSGLPDFSGLPSGFPTVSLVDSTLVEVVTASTASELEGRGTIGISGAGEISGLPSSELDISGRASGLPSGTELSGQASGSPDVSGEIPGLFGVSGQPSGFPDTSGETSGVTELSGLSSGQPGISGEASGVLYGTSQPFGITDLSGETSGVPDLSGQPSGLPGFSGATSGVPDLVSGTTSGSGESSGITFVDTSLVEVAPTTFKEEEGLGSVELSGLPSGEADLSGKSGMVDVSGQFSGTVDSSGFTSQTPEFSGLPSGIAEVSGESSRAEIGSSLPSGAYYGSGTPSSFPTVSLVDRTLVESVTQAPTAQEAGEGPSGILELSGAHSGAPDMSGEHSGFLDLSGLQSGLIEPSGEPPGTPYFSGDFASTTNVSGESSVAMGTSGEASGLPEVTLITSEFVEGVTEPTISQELGQRPPVTHTPQLFESSGKVSTAGDISGATPVLPGSGVEVSSVPESSSETSAYPEAGFGASAAPEASREDSGSPDLSETTSAFHEANLERSSGLGVSGSTLTFQEGEASAAPEVSGESTTTSDVGTEAPGLPSATPTASGDRTEISGDLSGHTSQLGVVISTSIPESEWTQQTQRPAETHLEIESSSLLYSGEETHTVETATSPTDASIPASPEWKRESESTAAAPARSCAEEPCGAGTCKETEGHVICLCPPGYTGEHCNIDQEVCEEGWNKYQGHCYRHFPDRETWVDAERRCREQQSHLSSIVTPEEQEFVNNNAQDYQWIGLNDRTIEGDFRWSDGHPMQFENWRPNQPDNFFAAGEDCVVMIWHEKGEWNDVPCNYHLPFTCKKGTVACGEPPVVEHARTFGQKKDRYEINSLVRYQCTEGFVQRHMPTIRCQPSGHWEEPQITCTDPTTYKRRLQKRSSRHPRRSRPSTAH

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Horse
78
Chicken
67
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P16112 As Substrate

Site PTM Type Enzyme
T371 O-Glycosylation
T376 O-Glycosylation
Y536 Phosphorylation
S540 Phosphorylation
N658 N-Glycosylation

Research Backgrounds

Function:

This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region.

PTMs:

Contains mostly chondroitin sulfate, but also keratan sulfate chains, N-linked and O-linked oligosaccharides. The release of aggrecan fragments from articular cartilage into the synovial fluid at all stages of human osteoarthritis is the result of cleavage by aggrecanase.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Restricted to cartilages.

Subunit Structure:

Interacts with FBLN1 (By similarity). Interacts with COMP.

Family&Domains:

Two globular domains, G1 and G2, comprise the N-terminus of the proteoglycan, while another globular region, G3, makes up the C-terminus. G1 contains Link domains and thus consists of three disulfide-bonded loop structures designated as the A, B, B' motifs. G2 is similar to G1. The keratan sulfate (KS) and the chondroitin sulfate (CS) attachment domains lie between G2 and G3.

Belongs to the aggrecan/versican proteoglycan family.

References

1). Hydrogen Ion Capturing Hydrogel Microspheres for Reversing Inflammaging. Advanced materials (Deerfield Beach, Fla.), 2024 (PubMed: 37699155) [IF=29.4]
2). An anti-inflammatory and neuroprotective biomimetic nanoplatform for repairing spinal cord injury. Bioactive Materials, 2022 (PubMed: 35845318) [IF=18.9]
3). Loss of DDRGK1 impairs IRE1α UFMylation in spondyloepiphyseal dysplasia. International Journal of Biological Sciences, 2023 (PubMed: 37781516) [IF=9.2]

Application: IF/ICC    Species: Mouse    Sample:

Figure 6 Loss of DDRGK1 or the K268R mutation led to IRE1α degradation and ER stress aggravation in the growth plate cells of mice in vivo. (A) Immunofluorescence analysis of SOX9, Aggrecan, IRE1α and CHOP expression in the lower limbs of the WT and cKO mice shown in Figure ​Figure1A;1A; the growth plate is the focus. (B) Quantification of the integrated optical density (IOD)/DAPI stain intensity levels of SOX9, Aggrecan, IRE1α and CHOP in the images shown in panel (A). (C) Alcian blue staining of primary chondrocytes from WT and mutant mice 9 days after high-density culturing in chondrogenesis medium. (D) Quantification of the relative IOD/area ratio in the Alcian blue-stained cells shown in panel (C). (E) Safranin O-Fast Green staining of the lower limbs in WT and mutant mice; the growth plate is the focus. (F) Quantification of the length of the hypertrophy zone (HZ) shown in panel (E). (G) TUNEL immunofluorescence staining of the lower limbs of the WT and cKO mice shown in Figure ​Figure1A1A with focus on the growth plate. (H) Quantification of the percentage of TUNEL-positive cells in the growth plate shown in panel (G). (I) Reverse transcription-quantitative PCR analysis performed to determine the relative mRNA expression levels of ATF4, BIP and CHOP in primary WT and Mutant mouse chondrocytes treated with or without thapsigargin (Tg) for 24 h; β-actin was the internal reference. (J) Western blot analysis of DDRGK1, IRE1α, BIP, ATF4 and CHOP of primary WT and mutant mouse chondrocytes treated with or without Tg for 24 h; β-actin was the loading control. (K) Immunofluorescence analysis of IRE1α, XBP-1s and CHOP expression in the lower limbs of the WT and mutant mice shown in panel (E); the growth plate is the focus. (L) Quantification of the IOD/DAPI stain intensity levels of IRE1α, XBP-1s and CHOP in the chondrocytes shown in panel (K). (M) Western blot analysis of cleaved and full-length PARP and cleaved Caspase 3 in primary in WT and mutant mouse chondrocytes treated with or without Tg for 24 h; β-actin was the loading control. All data are presented as the mean ± SD from three or more experiments.
4). TMF inhibits extracellular matrix degradation by regulating the C/EBPβ/ADAMTS5 signaling pathway in osteoarthritis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38554527) [IF=7.5]

Application: IHC    Species: Rat    Sample:

Fig. 1. The effect of TMF on the articular cartilage of OA rats (n = 6) was investigated. (A) The articular cartilage was stained with H/E. IHC assays were used to detect the altered expression of Aggrecan (B–C), ADAMTS5 (D–E), and Caspase3 (F–G) in the cartilage.
5). Vitamin K2 ameliorates osteoarthritis by suppressing ferroptosis and extracellular matrix degradation through activation GPX4's dual functions. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38759289) [IF=7.5]

Application: WB    Species: Rat    Sample:

Fig. 8. GPX4 inhibitor RSL3 substantially attenuates VK2 protection of chondrocytes. (A-I) WB results for GPX4, NFκB, pMAPK/MAPK, Aggrecan, CollagenⅡ, SOX9, MMP3, MMP13 and Tubulin; (J) Quantitive analysis of relative Glutathione Peroxidase Activity; (K-L) GSH contents and ratio of GSH/GSSG; (M) Quantitative results of MDA content assay.
6). MicroRNA-145 overexpression attenuates apoptosis and increases matrix synthesis in nucleus pulposus cells. LIFE SCIENCES, 2019 (PubMed: 30797016) [IF=6.1]

Application: WB    Species: rat    Sample: NP cells

Fig. 3. |miR-145 increased matrix metabolism in rat NP cells.(A, B) Real-time PCR analysis was performed to evaluate the mRNA expression of aggrecan (A) and collagen IIa (B) after a single transfection with agomir-145 or miR-155 inhibitors. (C, D, E) Western blotting (C) and subsequent densitometric analysis (D) demonstrated that aggrecan (C, E) and collagen IIa (D, E) protein were significantly upregulated in rat NP cells after transfection with agomir-145.
7). Lysyl oxidase inhibits TNF-α induced rat nucleus pulposus cell apoptosis via regulating Fas/FasL pathway and the p53 pathways. LIFE SCIENCES, 2020 (PubMed: 32979358) [IF=6.1]

Application: WB    Species: rat    Sample: NP cells

Fig. 3. |LOX improved the ECM expression pattern in TNF-α-treated rat NP cells. A. and B. Relative mRNA expressions of type II collagen and aggrecan in rat NP cells with different treatments were analyzed by RT-qPCR. C. Protein expressions of type II collagen and aggrecan in rat NP cells with different treatments were analyzed by western blot.
8). L-Glutamine alleviates osteoarthritis by regulating lncRNA-NKILA expression through the TGF-β1/SMAD2/3 signalling pathway. Clinical Science, 2022 (PubMed: 35730575) [IF=6.0]
9). An Inducible Nitric Oxide Synthase Dimerization Inhibitor Prevents the Progression of Osteoarthritis. Frontiers in pharmacology, 2022 (PubMed: 35910349) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 4 Compound 22o alleviates IL-1β-induced chondrocyte inflammatory responses and ECM degradation. Rat chondrocytes were treated with different concentrations of compound 22o in the presence or absence of IL-1β (10 ng/ml) for 24 h. (A) Western blots and (B) quantitative analysis of COX-2. (C) Western blots and (D) quantitative analysis of ACAN, COL2A1 and MMP3. GAPDH was employed as the internal control (n = 3). (E) Quantification of mRNA levels for COX-2, ACAN, COL2A1 and MMP3. Fold changes relative to control group are shown (n = 3). #p < 0.05 vs. control group; *p < 0.05 vs. IL-1β group.
10). TRIM38 protects chondrocytes from IL-1β-induced apoptosis and degeneration via negatively modulating nuclear factor (NF)-κB signaling. International Immunopharmacology, 2021 (PubMed: 34426118) [IF=5.6]

Application: WB    Species: Mouse    Sample: chondrocytes

Fig. 4. The effects of TRIM38 depletion on IL-1β-induced degeneration of chondrocytes. (A, B) The effects of TRIM38 overexpression on the levels of MMP-3, MMP- 13, ACAN, and COL2A1 were measured via western blotting (n = 3). (C, D) The effects of TRIM38 knockdown on the levels of MMP-3, MMP-13, ACAN, and COL2A1 were assessed via western blotting (n = 3). **p < 0.01.
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.